↓ Skip to main content

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

Overview of attention for article published in Orphanet Journal of Rare Diseases, May 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
8 X users

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
97 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Published in
Orphanet Journal of Rare Diseases, May 2014
DOI 10.1186/1750-1172-9-75
Pubmed ID
Authors

Tim A Kanters, Iris Hoogenboom-Plug, Maureen PMH Rutten-Van Mölken, W Ken Redekop, Ans T van der Ploeg, Leona Hakkaart

Abstract

Infantile Pompe disease is a rare metabolic disease. Patients generally do not survive the first year of life. Enzyme replacement therapy (ERT) has proven to have substantial effects on survival in infantile Pompe disease. However, the costs of therapy are very high. In this paper, we assess the cost-effectiveness of enzyme replacement therapy in infantile Pompe disease.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
United States 1 1%
Unknown 95 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 15%
Student > Ph. D. Student 14 14%
Other 10 10%
Student > Master 10 10%
Student > Doctoral Student 9 9%
Other 17 18%
Unknown 22 23%
Readers by discipline Count As %
Medicine and Dentistry 33 34%
Agricultural and Biological Sciences 7 7%
Biochemistry, Genetics and Molecular Biology 6 6%
Social Sciences 6 6%
Economics, Econometrics and Finance 5 5%
Other 16 16%
Unknown 24 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2017.
All research outputs
#2,376,262
of 25,374,917 outputs
Outputs from Orphanet Journal of Rare Diseases
#289
of 3,105 outputs
Outputs of similar age
#23,386
of 241,956 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#3
of 47 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,956 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.